Abstract

This study was made to determine the clinical and pathological features and incidences of tumors according to the results obtained from the samples taken during an appendectomy, to evaluate the post-diagnosis treatments and the survival time of patients. The data of this retrospective study had from the files of 4813 patients who were operated with pre-diagnosis of acute appendicitis at Ankara Atatürk Training and Research Hospital between 2007,-2017. Fifteen (0.31%) of the patients who underwent appendectomy were detected to have appendix tumors. According to the histopathological classification of tumors of these patients, it was determined that 8 of them had a carcinoid tumor, 6 of them had mucinous adenocarcinoma and 1 of them had adenocarcinoma. The mean age of the patients with carcinoid tumor was 30.29 ± 7.95 and the mean age of the patients with mucinous adenocarcinoma was 65 ± 18.81. It has been determined that women develop two times more appendix tumors than men. Nine patients with a tumor diameter less than 1 cm had only appendectomy operation and it was determined that tumors did not recurrence after the follow-up. Three patients with postoperative mesoappendix involvement underwent right hemicolectomy in the second operation. Preoperative computed tomography revealed periappendicular mass in 3 patients. In addition to right hemicolectomy, omentectomy, peritonectomy and lymph node dissection were performed in these three patients with suspected malignancy. The five-year survival of patients was found to be 100.0% in patients with carcinoid tumors and 67.0% in patients with mucinous adenocarcinomas. In conclusion, the majority of appendiceal tumors in our study that were found to be more widespread in women than in men were detected incidentally. The prognosis and survival rates of patients with carcinoid tumors were better than mucinous adenocarcinomas. Therefore, to made follow-up and treatment of the patients according to the report obtained after histopathologic examination of the appendix tumor is important.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.